325 related articles for article (PubMed ID: 18234424)
1. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
Cancer Treat Rev; 2008 May; 34(3):223-30. PubMed ID: 18234424
[TBL] [Abstract][Full Text] [Related]
2. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla JP; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
J Clin Oncol; 2001 Feb; 19(3):612-20. PubMed ID: 11157010
[TBL] [Abstract][Full Text] [Related]
3. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
4. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Dang C; Lin N; Moy B; Come S; Sugarman S; Morris P; Abbruzzi A; Chen C; Steingart R; Patil S; Norton L; Winer E; Hudis C
J Clin Oncol; 2010 Jun; 28(18):2982-8. PubMed ID: 20479410
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Elling D
Br J Cancer; 2006 May; 94(9):1237-44. PubMed ID: 16622463
[TBL] [Abstract][Full Text] [Related]
8. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
11. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Untch M; Fasching PA; Konecny GE; von Koch F; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Schuster T; Nekljudova V; Lebeau A; Loibl S; von Minckwitz G;
Ann Oncol; 2011 Sep; 22(9):1988-1998. PubMed ID: 21385882
[TBL] [Abstract][Full Text] [Related]
12. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl HM; Hiller L; Howard HC; Dunn JA; Young J; Bowden SJ; McDermaid M; Waterhouse AK; Wilson G; Agrawal R; O'Reilly S; Bowman A; Ritchie DM; Goodman A; Hickish T; McAdam K; Cameron D; Dodwell D; Rea DW; Caldas C; Provenzano E; Abraham JE; Canney P; Crown JP; Kennedy MJ; Coleman R; Leonard RC; Carmichael JA; Wardley AM; Poole CJ;
Lancet Oncol; 2017 Jun; 18(6):755-769. PubMed ID: 28479233
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML; Berry DA; Cirrincione C; Hudis C; Winer EP; Gradishar WJ; Davidson NE; Martino S; Livingston R; Ingle JN; Perez EA; Carpenter J; Hurd D; Holland JF; Smith BL; Sartor CI; Leung EH; Abrams J; Schilsky RL; Muss HB; Norton L
J Clin Oncol; 2003 Apr; 21(8):1431-9. PubMed ID: 12668651
[TBL] [Abstract][Full Text] [Related]
14. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
15. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Shulman LN; Cirrincione CT; Berry DA; Becker HP; Perez EA; O'Regan R; Martino S; Atkins JN; Mayer E; Schneider CJ; Kimmick G; Norton L; Muss H; Winer EP; Hudis C
J Clin Oncol; 2012 Nov; 30(33):4071-6. PubMed ID: 22826271
[TBL] [Abstract][Full Text] [Related]
16. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Swain SM; Tang G; Geyer CE; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N
J Clin Oncol; 2013 Sep; 31(26):3197-204. PubMed ID: 23940225
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J
Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
19. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
20. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Hudis C; Fornier M; Riccio L; Lebwohl D; Crown J; Gilewski T; Surbone A; Currie V; Seidman A; Reichman B; Moynahan M; Raptis G; Sklarin N; Theodoulou M; Weiselberg L; Salvaggio R; Panageas KS; Yao TJ; Norton L
J Clin Oncol; 1999 Apr; 17(4):1118. PubMed ID: 10561169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
